Physician profile
Thomas R Mann
NPI 1740370691
$4,102.92
in general payments reported to CMS, 2019-2025
32 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $442 · 2021: $592 · 2022: $458 · 2023: $899 · 2024: $732 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.70 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $708.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $673.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $539.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $414.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $270.18 | 2020-2023 | Veozah, Myrbetriq |
| Lilly USA, LLC | $179.91 | 2020-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $164.35 | 2019-2021 | |
| Axsome Therapeutics, INC. | $116.16 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $105.75 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.81 | 2022-2025 | |
| Pfizer INC. | $81.11 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $69.75 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $66.80 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.18 | 2019-2023 | Synjardy, Jardiance |
| Ardelyx, INC. | $57.11 | 2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $47.41 | 2019-2020 | |
| Dexcom, INC. | $46.93 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $46.44 | 2019 | |
| Idorsia Pharmaceuticals US INC | $43.76 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $43.64 | 2023-2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $42.59 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $41.57 | 2023 | Gvoke Hypopen |
| Eisai INC. | $35.43 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $32.33 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.68 | 2023 | |
| Exact Sciences Corporation | $20.80 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.79 | 2020 | |
| Phathom Pharmaceuticals, INC. | $15.32 | 2025 | Voquezna |
| Boston Scientific Corporation | $15.07 | 2022 | |
| Corium, LLC | $13.37 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $12.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.